Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023957 | 0.87 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7031336 | 0.83 | HTR2A (0.45) | HTR2AHTR2CHTR7HTR6SLC6A4 | |
| SCHEMBL7027592 | 0.83 | HTR2A (0.45) | HTR2AHTR2CHTR7HTR6KCNH2 | |
| SCHEMBL7026680 | 0.82 | HTR2A (0.55) | HTR2AHTR2CHTR7HTR6KCNH2 | |
| SCHEMBL7029871 | 0.80 | HTR2A (0.47) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7023753 | 0.80 | HTR2A (0.50) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7022347 | 0.80 | HTR2A (0.50) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7028836 | 0.79 | HTR1A (0.56) | HTR2AHTR2CKCNH2SLC6A4 | |
| SCHEMBL7031635 | 0.79 | HTR2A (0.57) | HTR2AHTR2CKCNH2 | |
| SCHEMBL7032512 | 0.78 | CARM1 (0.57) | HTR2AHTR2CHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
| EP-1246803-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT 2A? RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051469-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT2A RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | HTR2A 1/4885HTR2C 5/4885HTR7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.